← 返回

NK 细胞:高级别浆液性卵巢癌有效治疗中缺失的一环

英文原题:Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.

查看英文原题

Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.

PubMed 2022/02/22(内容时间) Curr Treat Options Oncol Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

卵巢癌(OC),尤其是高级别浆液性癌(HGSC),是一种高度异质性恶性肿瘤,根治性治疗选择有限且复发率高。OC与免疫系统的相互作用可能促成免疫编辑和免疫逃逸,而现行标准疗法也会影响肿瘤微环境中的免疫细胞浸润和功能。自然杀伤(NK)细胞参与肿瘤免疫监视和免疫编辑,也可被治疗激活;但有意识地通过治疗最大限度增强NK细胞反应性以治疗HGSC,目前仍处于起步阶段。NK细胞可能是HGSC免疫治疗的理想靶点。NK细胞功能多样且已知参与免疫监视,因此是实现更精准、有效HGSC治疗的有吸引力候选者。NK细胞功能能力因受体表达和遗传差异而异,并对其抗癌活性产生重要影响。研究HGSC与NK细胞的相互作用,有助于确定预测患者良好结局的特征;但由于HGSC高度多样,可能需要联合疗法或同时靶向肿瘤多个并存特征,以避免肿瘤逃逸和复发。理想疗法应促进NK细胞浸润和活性,逆转肿瘤微环境中的免疫抑制,并使效应细胞能够攻击构成HGSC的多种亚群。

展开英文摘要原文

Ovarian cancer (OC), especially high-grade serous cancer (HGSC), is a highly heterogeneous malignancy with limited options for curative treatment and a high frequency of relapse. Interactions between OC and the immune system may permit immunoediting and immune escape, and current standard of care therapies can influence immune cell infiltration and function within the tumor microenvironment. Natural killer (NK) cells are involved in cancer immunosurveillance and immunoediting and can be activated by therapy, but deliberate approaches to maximize NK cell reactivity for treatment of HGSC are in their infancy. NK cells may be the ideal target for immunotherapy of HGSC.

The diverse functions of NK cells, and their established roles in immunosurveillance, make them attractive candidates for more precise and effective HGSC treatment. NK cells' functional capabilities differ because of variation in receptor expression and genetics, with meaningful impacts on their anticancer activity.

Studying HGSC:NK cell interactions will define the features that predict the best outcomes for patients with the disease, but the highly diverse nature of HGSC will likely require combination therapies or approaches to simultaneously target multiple, co-existing features of the tumor to avoid tumor escape and relapse.

We expect that the ideal therapy will enable NK cell infiltration and activity, reverse immunosuppression within the tumor microenvironment, and enable effector functions against the diverse subpopulations that comprise HGSC.

论文信息

作者
Pugh-Toole M、Nicolela AP、Nersesian S、Leung BM、Boudreau JE
第一作者单位
Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.Canada
通讯作者单位
Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada. Jeanette.boudreau@dal.ca.Canada
文献类型
非美国政府资助研究 · 综述
期刊
Current treatment options in oncology2022 Feb
原文标识
PubMed 35192139 · DOI 10.1007/s11864-021-00929-x